Nexalin Technology to Participate in the 2025 Maxim Growth Summit

HOUSTON, TX — October 10, 2025 — Leads & Copy — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) will participate in the 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. The event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries.

Attendees can engage with Nexalin’s management and learn about its proprietary, non-invasive neurostimulation which is a drug-free, clinically proven treatment with the potential to scale worldwide.

Nexalin designs and develops neurostimulation products to combat the global mental health epidemic. Its products are non-invasive and undetectable and provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues, and its neurostimulation medical devices can penetrate structures deep in the mid-brain. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.

Contact: Crescendo Communications, LLC, Tel: (212) 671-1020, Email: NXL@crescendo-ir.com

Source: Nexalin Technology, Inc.

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.